| Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. | |
| | |
MedLine Citation:
|
PMID: 22370904 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The long-term outcome of patients with chronic phase chronic myeloid leukemia treated with imatinib after failure of interferon alpha therapy has not been detailed. METHODS: In total, 368 patients were analyzed. Univariate and multivariate survival analyses were conducted using standard statistical methods. RESULTS: Overall, 247 patients (67%) achieved a complete cytogenetic response (CCyR). Of the 327 patients who were studied, 207 patients (63%) achieved a major molecular response (MMR), and 99 patients (30%) had undetectable breakpoint cluster region/c-abl oncogene (BCR-ABL) levels at some time during therapy. The estimated 10-year survival rate was 68%, the progression-free survival rate was 67%, and the event-free survival rate was 51%. In multivariate analysis, age ≥ 60 years, hemoglobin <10 g/dL, bone marrow basophils ≥ 5%, any peripheral blasts, and clonal evolution were independent adverse factors for survival. The estimated 7-year survival rate according to the presence of no factors (n = 154), 1 or 2 factors (n = 190), or ≥ 3 factors (n = 24) were 93%, 70%, and 25%, respectively (P < .01). Achieving an MMR, a CCyR, or a partial cytogenetic response at 12 months was associated with significantly better 10-year survival rate in a landmark analysis (10-year survival rate, 80%-90%) compared with achieving a minor cytogenetic response or a complete hematologic response (10-year survival rate, 55%-65%) or another response (10-year survival rate, 10%). In a landmark analysis that included imatinib response at 12 months, achieving a major cytogenetic response or better (hazard ratio, 0.12; P < .001) and achieving a complete hematologic response or a minor cytogenetic response (hazard ratio, 0.36; P = .003) were significant favorable prognostic factors. CONCLUSIONS: The current results indicated that the estimated 10-year survival rate of 68% for patients with chronic myeloid leukemia who receive imatinib after failure on interferon has improved. |
| | |
Authors:
|
Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi; Elias Jabbour; Jianqin Shan; Jorge Cortes |
Related Documents
:
|
22532584 - Concordance among gene expression-based predictors for er-positive breast cancer treate... 22767314 - Mri volume measurements compared with the recist 1.1 for evaluating the response to neo... 6587604 - Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the s... 22689804 - Surveillance computed tomography imaging and detection of relapse in intermediate- and ... 11249054 - Prognostic factors and long-term survival in 585 patients with metastatic breast cancer... 9038274 - Treatment of stage iv "high-grade" endometrial stromal sarcoma with ifosfamide, adriamy... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2012-02-27 |
Journal Detail:
|
Title: Cancer Volume: 118 ISSN: 1097-0142 ISO Abbreviation: Cancer Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-06-07 Completed Date: 2012-08-15 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 3116-22 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2011 American Cancer Society. |
Affiliation:
|
Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Female Follow-Up Studies Fusion Proteins, bcr-abl / drug effects, genetics Humans Interferon-alpha / therapeutic use* Leukemia, Myeloid, Chronic-Phase / drug therapy*, mortality Male Middle Aged Piperazines / administration & dosage* Prognosis Protein Kinase Inhibitors / therapeutic use* Pyrimidines / administration & dosage* Retreatment Survival Rate Treatment Failure Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
P01 CA049639/CA/NCI NIH HHS; UL1 RR024148/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Fusion Proteins, bcr-abl; 0/Interferon-alpha; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; BKJ8M8G5HI/imatinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic significance of peritoneal lavage cytology in patients with colorectal cancer.
Next Document: Adherence to Active Play and Electronic Media Guidelines in Preschool Children: Gender and Parental ...